CRISPR Therapeutics AG (CRSP)

51.89
NASDAQ : Health Technology
Prev Close 51.89
Day Low/High 0.00 / 0.00
52 Wk Low/High 16.16 / 73.90
Avg Volume 847.50K
Exchange NASDAQ
Shares Outstanding 47.59M
Market Cap 2.53B
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Market's Leap of Faith: Cramer's 'Mad Money' Recap (Wednesday 8/8/18)

Market's Leap of Faith: Cramer's 'Mad Money' Recap (Wednesday 8/8/18)

Jim Cramer talks about which companies and CEOs are being given the benefit of the doubt -- and which actually deserve it.

Visa, Zuora, CRISPR, Tractor Supply: 'Mad Money' Lightning Round

Visa, Zuora, CRISPR, Tractor Supply: 'Mad Money' Lightning Round

Jim Cramer weighs in on Visa, Zuora, CRISPR, Tractor Supply, Enable Midstream Partners, Eagle Materials, Sempra Energy.

First Week Of September 21st Options Trading For CRISPR Therapeutics (CRSP)

First Week Of September 21st Options Trading For CRISPR Therapeutics (CRSP)

Investors in CRISPR Therapeutics AG saw new options begin trading this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Abingworth Raises $315m For ABV VII 12th Life Sciences Fund

Abingworth Raises $315m For ABV VII 12th Life Sciences Fund

LONDON, July 9, 2018 /PRNewswire/ -- Abingworth, the international investment group dedicated to life sciences, today announced the final closing of its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million.

Snap, Gilead Sciences, Cronos Group: 'Mad Money' Lightning Round

Snap, Gilead Sciences, Cronos Group: 'Mad Money' Lightning Round

Jim Cramer takes a look at Snap, Gilead Sciences, Cronos Group, TrustCo Bank, CRISPR Therapeutics, Iron Mountian, Prudential and more.

The Trouble With Trump's Tariffs: Cramer's 'Mad Money' Recap (Friday 6/22/18)

The Trouble With Trump's Tariffs: Cramer's 'Mad Money' Recap (Friday 6/22/18)

Trump's doubling down on trade issues. If you can't stand the pressure, then raise cash. Jim Cramer has your game plan for next week.

Intellia Therapeutics Has Upside in Its DNA

Intellia Therapeutics Has Upside in Its DNA

The setup here is appealing enough to take a small, aggressive shot on the long side.

First Week Of CRSP January 2019 Options Trading

Investors in CRISPR Therapeutics AG saw new options begin trading this week, for the January 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer weighs in on Royal Caribbean, Allergan, Tyson Foods, Carrizo Oil & Gas, Valeant Pharmaceuticals, Okta, CRISPR Therapeutics and more.

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Jim Cramer says the hope that the trade dispute with China can be worked out was the fuel for this rally.

CRSP Crosses Above Average Analyst Target

In recent trading, shares of CRISPR Therapeutics AG have crossed above the average analyst 12-month target price of $62.20, changing hands for $65.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FF, FSLR, GVP, IMMR, QBAK, RGNX, SSRM, VSH Downgrades: COMM, CRSP, IMKTA, LBRDA, WIT Initiations: KRP, NAOV Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, ATRC, BKE, CRSP, HALO Downgrades: GIFI, GTE, MGI, NNI, RBBN, SHAK, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

The Confidence in the Dip Buyers Has Weakened

The Confidence in the Dip Buyers Has Weakened

The bears are likely to be increasingly bold if there's a failed bounce.

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Jim Cramer highlights Anthem, A.O. Smith, Tableau Software, Electro Scientific Industries, CRISPR Therapeutics.

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Jim Cramer says this is the scary process that gets us back to where we can maintain a real, not parabolic, advance.

Vertex And CRISPR Therapeutics To Co-Develop And Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell Disease And ß-Thalassemia

Vertex And CRISPR Therapeutics To Co-Develop And Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell Disease And ß-Thalassemia

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as...

CRISPR Therapeutics Announces Oral Presentation Of New Data On CTX001, A CRISPR Gene-Edited Therapy For ¿-Thalassemia And Sickle Cell Disease, At The ASH Annual Meeting

CRISPR Therapeutics Announces Oral Presentation Of New Data On CTX001, A CRISPR Gene-Edited Therapy For ¿-Thalassemia And Sickle Cell Disease, At The ASH Annual Meeting

CRISPR gene-editing in hematopoietic stem cells demonstrates potential to treat ß-thalassemia and sickle cell disease through upregulation of fetal hemoglobin

CRISPR Therapeutics Submits First Clinical Trial Application For A CRISPR Gene-Edited Therapy, CTX001 In ¿-thalassemia

CRISPR Therapeutics Submits First Clinical Trial Application For A CRISPR Gene-Edited Therapy, CTX001 In ¿-thalassemia

-Phase 1/2 trial in ß-thalassemia expected to begin in 2018-

TheStreet Quant Rating: D+ (Sell)